-
Mashup Score: 17New approaches to reduce recurrent PCI: to angioplasty and beyond! - 12 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 14New approaches to reduce recurrent PCI: to angioplasty and beyond! - 12 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0New approaches to reduce recurrent PCI: to angioplasty and beyond! - 12 month(s) ago
Pierre Sabouret, Stéphane Manzo-Silberman, MD, Mirvat Alasnag, Marinos Fysekidis, Martha Gulati, MD, MS, Giuseppe Galati, Luigi Spadafora, Maciej Banach, Giusep
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome - 1 year(s) ago
Many patients require revascularization after an index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothr…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome - 1 year(s) ago
Many patients require revascularization after an index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothr…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome - 1 year(s) ago
Many patients require revascularization after an index acute coronary syndrome (ACS). Lipoprotein(a) is thought to play a pathogenic role in atherothr…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 - 1 year(s) ago
MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercho…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8
Abstract. In patients admitted for acute coronary syndrome (ACS), the guidelines of the European Society of Cardiology give a Class I, Level A recommendation fo
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2Inhibiteurs de PCSK9 : quelle place dans la prise en charge actuelle des dyslipidémies ? - 1 year(s) ago
La protéine PCSK9 régule l’activité des LDL-récepteurs.Les mutations gain de fonction de PCSK9 sont une des causes génétiques d’hypercholestérolémie f…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 4
AbstractObjective. To evaluate the specific effects of PCSK9 inhibitors (i.e. alirocumab and evolocumab) on major cardiovascular events (MACE) and lipid profile
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
RT @SABOURETCardio: #MyEAS #EASCongress2023. How to reduce #MACE with new approaches #LLT #PCSK9i #EPA #GLP1RA https://t.co/L2ArgCKkyb